Arcutis Biotherapeutics, Inc.
ARQT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001787306
In the last 90 days, Arcutis Biotherapeutics, Inc. insiders filed 0 open-market purchases and 12 sales; 272 institutions reported holding it in 13F filings for Q2 2026, worth $3.45B in total; no superinvestor holds it.
13F holders, Q4 2021
Institutional positions in Arcutis Biotherapeutics, Inc. as of Dec 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 93
- −9 vs. Q3 2021
- Shares held
- 46.4M
- +674.2K (+1.5%) vs. Q3 2021
- Total value
- $961.8M
- −$129.6M (−11.9%) vs. Q3 2021
- New holders
- 12
- 40 more added
- Sold out
- 21
- 19 more reduced
1 institution that held it in Q3 2021 haven't filed for Q4 2021 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ARQT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 272 | $3.45B |
| Q1 2026 | 270 | $3.12B |
| Q4 2025 | 283 | $3.75B |
| Q3 2025 | 239 | $2.37B |
| Q2 2025 | 230 | $1.78B |
| Q1 2025 | 241 | $1.97B |
| Q4 2024 | 208 | $1.79B |
| Q3 2024 | 188 | $1.20B |
| Q2 2024 | 186 | $1.18B |
| Q1 2024 | 168 | $1.24B |
| Q4 2023 | 133 | $327.1M |
| Q3 2023 | 134 | $356.7M |
| Q2 2023 | 136 | $684.0M |
| Q1 2023 | 144 | $787.6M |
| Q4 2022 | 141 | $979.6M |
| Q3 2022 | 139 | $1.13B |
| Q2 2022 | 115 | $1.05B |
| Q1 2022 | 106 | $929.8M |
| Q4 2021 | 93 | $961.8M |
| Q3 2021 | 103 | $1.09B |
| Q2 2021 | 102 | $1.24B |
| Q1 2021 | 94 | $1.35B |
Institutions, Q4 2021
Shares, value and share of portfolio for each institution holding Arcutis Biotherapeutics, Inc.; share changes are against Q3 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Birchview Capital, LP | 0 | $0 | 0.00% | −9,000−100.0% | Sold out |
| Penn Mutual Asset Management, LLC | 0 | $0 | 0.00% | −5,413−100.0% | Sold out |
| Meeder Asset Management Inc | 0 | $0 | 0.00% | −2,683−100.0% | Sold out |
| The PNC Financial Services Group, Inc. | 0 | $0 | 0.00% | −1,500−100.0% | Sold out |
| Penserra Capital Management LLC | 0 | $0 | 0.00% | −1,155−100.0% | Sold out |
| Laurel Wealth Advisors LLC | 0 | $0 | 0.00% | −440−100.0% | Sold out |
| Glen Eagle Advisors, LLC | 0 | $0 | 0.00% | −400−100.0% | Sold out |
| Carroll Financial Associates, Inc. | 0 | $0 | 0.00% | −400−100.0% | Sold out |
| Trustcore Financial Services, LLC | 0 | $0 | 0.00% | −215−100.0% | Sold out |
| US Bancorp | 0 | $0 | 0.00% | −114−100.0% | Sold out |
| Steward Partners Investment Advisory, LLC | 0 | $0 | 0.00% | −100−100.0% | Sold out |
| Toth Financial Advisory Corp | 0 | $0 | 0.00% | −50−100.0% | Sold out |
| Firestone Capital Management | 0 | $0 | 0.00% | −50−100.0% | Sold out |
| Prentice Wealth Management LLC | 0 | $0 | 0.00% | −50−100.0% | Sold out |
| Berman Capital Advisors, LLC | – | – | – | – | Not filed |